Click here: to donate by Credit Card
Or here: to donate by PayPal
Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794
Thank you very much and God bless you.
Posted on 03/06/2026 10:35:42 AM PST by nickcarraway
Could bacteria replace your eye drops? Mice study says maybe
In A Nutshell
-Researchers engineered a naturally occurring eye bacterium to secrete an anti-inflammatory healing protein directly on the eye’s surface
-In mice, a single course of three bacterial applications kept the microbes active for 12 weeks and sped corneal wound healing
-The bacteria preserved the eye’s normal immune defenses and did not increase susceptibility to infection
-A human version of the therapy showed early promise in lab tests, but clinical use in people is still years away
Forget the eye drops. Researchers at the University of Pittsburgh have engineered a living bacterium to take up long-term residence on the eye’s surface and quietly deliver anti-inflammatory therapy around the clock, no dropper bottle required.
More than a million Americans visit emergency rooms for corneal wounds each year, and standard treatment demands medicated drops applied as often as every two hours. Most patients can’t keep up. Studies cited in the new research found that older patients forget their drops 40% of the time, with full adherence dropping to just 10% when multiple daily applications are required. When inflammation goes unmanaged after a corneal injury, healing slows, nerves can be damaged, and vision can suffer permanently.
A new study published in Cell Reports shows there may be a better way. Scientists genetically modified Corynebacterium mastitidis, a harmless bacterium that naturally colonizes mouse eyes, to continuously secrete a healing protein called interleukin-10. In mice, a single course of three bacterial applications kept the engineered microbes active on the ocular surface for the entire 12-week study period, and corneal wounds healed measurably faster as a result.
Why the Eye Is So Hard to Treat Tears are the enemy of eye medication. Every blink sweeps the corneal surface clean, washing away drops before they can do much good. Injections beneath the eye’s outer membrane work better but are invasive and impractical for daily use. What clinicians have long needed is something that stays put.
That is where C. mast comes in. Naturally occurring on mouse eyes, the bacterium does not trigger inflammation or cause disease in healthy animals. It simply lives there. First author Jackie Shane and corresponding author Anthony J. St. Leger and colleagues at the University of Pittsburgh saw it as a delivery vehicle waiting to be repurposed.
Their target molecule was interleukin-10, or IL-10, a protein the immune system uses to dial back inflammation and encourage tissue repair. Getting C. mast to release IL-10 outward rather than keep it inside the cell required finding a secretion signal, a short genetic sequence that acts as a shipping label, telling the bacterium to push a specific protein through its cell wall and into the surrounding environment. Researchers screened hundreds of bacterial mutants to find one with strong natural secretion activity, then used that sequence to direct IL-10 out of the cell.
Engineering the Microbe and Testing It in Mice
With a secretion signal in hand, the team attached it to the gene for mouse IL-10 and inserted the whole package into the C. mast genome using a transposon, a molecular tool for writing new instructions into bacterial DNA. From more than 200 engineered candidates, two strains proved fit enough to colonize mouse eyes and hold their position for the full observation period without being cleared by the immune system.
Colonized animals then received standardized 2.5-millimeter corneal abrasions, and wound closure was tracked over 19 hours. Eyes colonized with IL-10-secreting bacteria healed faster than those treated with unmodified bacteria or saline. To rule out any other explanation, researchers blocked the IL-10 receptor in a separate group of animals before wounding. With IL-10 signaling chemically neutralized, the healing advantage disappeared, confirming that the engineered protein was directly responsible.
Just as important was what the bacteria did not do. IL-17 immunity, the eye’s front-line defense against spontaneous infection, remained intact in colonized animals. The engineered microbe was doing its therapeutic job without dismantling the immune responses that keep the eye safe.
A Human Version Shows Early Promise Treating mice is one thing. To move toward human patients, the team engineered a separate C. mast strain to secrete human IL-10. In lab dishes, fluid from these bacteria sped wound closure in human corneal cells. In mice colonized with the human IL-10 strain, corneas healed faster, inflammatory immune cells were reduced after injury, and eyes remained resistant to Pseudomonas aeruginosa, a bacterium behind some of the most severe corneal infections seen in clinics.
“This proof of concept opens the possibility of harnessing the ocular microbiome to treat ocular diseases,” the authors wrote.
bacteria eye drops
Study visual abstract. (Credit: St. Leger, et al., Cell Reports, DOI: 10.1016/j.celrep.2026.117064)
One Treatment, Months of Coverage
Researchers are candid that this technology needs more development before it could ever reach a patient. One unresolved challenge is dosage control. Despite confirmed colonization and clear wound-healing effects, free IL-10 was undetectable in tear fluid, suggesting the protein is active at very low local concentrations or absorbed immediately by surrounding tissue. Future iterations may use genetic switches to tune or stop output as needed.
Still, the broader picture is worth sitting with. A person with a corneal wound or a chronic ocular surface disease currently manages their condition one drop at a time, multiple times a day, for months or years. What this research proposes, at least in principle, is trading that burden for a single colonization event and letting the bacteria handle the rest. Whether that becomes a clinical reality depends on years of additional work, but the biology, at least in mice and in human cells, indicates it can be done.
Disclaimer: This research was conducted in mice and in laboratory cell cultures. No human clinical trials have been conducted. The findings should not be interpreted as proof that this therapy is safe or effective in people. Consult a qualified medical professional regarding any eye health concerns.
Paper Notes
Limitations
All in vivo work was conducted in mice. Human data came from in vitro experiments using corneal cell lines and donated blood samples, with no human subjects enrolled. Free IL-10 in tear fluid was undetectable despite confirmed colonization, meaning precise dosing remains an unsolved problem. Colonization was observed for up to 12 weeks, so long-term effects including possible immune suppression, microbial imbalance, or other complications remain unknown. Authors note the system currently lacks a built-in off switch, and that developing selective removal mechanisms will likely be necessary before any clinical testing can proceed.
Funding and Disclosures
Work was supported by NIH grants R01EY032482, U24EY035102, T32EY017271, EY036686, and CORE Grant P30 EY08098 to the Department of Ophthalmology at the University of Pittsburgh School of Medicine, along with the Hillman Innovation Exploratory Award, the Eye and Ear Foundation of Pittsburgh, and unrestricted grants from Research to Prevent Blindness. Authors disclosed a provisional patent application (Pitt. ref. no. 06908; KS ref. no. 8123-113563-01) related to the described technology.
Publication Details
Authors: Jackie Shane, Matthew Evans, Yannis Rigas, Robert M.Q. Shanks, and Anthony J. St. Leger, all affiliated with the Department of Ophthalmology, University of Pittsburgh. St. Leger also holds an appointment in the Department of Immunology at the University of Pittsburgh and served as lead contact. Paper title: “Genetically engineered eye-colonizing microbes that deliver the anti-inflammatory cytokine interleukin-10 enhance corneal tissue repair.” Published in Cell Reports, 2026. DOI: https://doi.org/10.1016/j.celrep.2026.117064
|
|
Click here: to donate by Credit Card Or here: to donate by PayPal Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794 Thank you very much and God bless you. |
The three blind have been cured.
That's pretty much what I would have done.
Didn’t Ray Milland star in this movie?
I was hoping for help on macular degeneration. Not today.
I’m getting some serious “I Am Legend” style vibes here.
Hello, I am going to try out some bacterial eye drops on you, OK?
The () you are! Where’s the exit?
No thanks.
Eye yogurt?
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.